Subscriber Login

  • This account has no valid subscription for this site.

Forgotten your password?

Show Summary Details
Page of

Multiple-Drug Regimens 

Multiple-Drug Regimens


Margaret A. Winker

Page of

PRINTED FROM AMA MANUAL OF STYLE ONLINE ( © American Medical Association, 2009. All Rights Reserved. Under the terms of the license agreement, an individual user may print out a PDF of a single chapter of a title in AMA Manual of Style Online for personal use (for details see Privacy Policy). 

Subscriber: null; date: 30 September 2016

Multiple-Drug Regimens

Regimens that include multiple drugs may be referred to by an abbreviation after the nonproprietary names of the drugs have been provided at first mention (see also 15.4.12, Drug Abbreviations, and 14.11, Abbreviations, Clinical, Technical and Other Common Terms). Drug regimens used in oncology frequently are referred to by abbreviations of combinations of antineoplastic agents, but often the abbreviations are not derived from the INNs. For example, the letter O in MOPP is derived from Oncovin, the proprietary name for vincristine sulfate, and the A in ABVD is derived from Adriamycin, the proprietary name for doxorubicin hydrochloride. When the abbreviation is expanded the proprietary names may be provided after the nonproprietary names to clarify the origin of the abbreviation.

The MOPP (methotrexate, vincristine sulfate [Oncovin], prednisone, and procarbazine hydrochloride) regimen for advanced Hodgkin disease was compared with MOPP alternating with ABVD (doxorubicin hydrochloride [Adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine).

Previous | Next